$PCYC Headlines Mid-caps rattle cage on all-time highs

New Post Public Reply Private Reply Replies (0) Message Board

Jan 6, 2015 at 12:45 PM

$PCYC Headlines

Mid-caps rattle cage on all-time highs 10:58 a.m. Nov. 13, 2014 - Michael Ashbaugh
Market technicals bend, but don’t break 9:21 a.m. Sept. 11, 2014 - Michael Ashbaugh
Charting the U.S. markets’ next technical tests 10:32 a.m. Aug. 4, 2014 - Michael Ashbaugh
5 stocks to watch 12:50 p.m. July 30, 2014 - The Trading Deck
Biotech hammered as ETFs down 5%, while some stocks fall 10% 12:55 p.m. April 10, 2014 - Russ Britt
Is biotech caught in a bubble, and is it popping? 12:13 p.m. April 8, 2014 - Russ Britt
S&P 500’s slow-motion breakout attempt ‘rages on’ 11:43 a.m. Feb. 27, 2014 - Michael Ashbaugh
FDA approval of leukemia treatment boosts shares of Pharmacyclics 1:57 p.m. Feb. 12, 2014 - Russ Britt
Pharmacyclics shares soar after panel says cancer drug met goals 12:09 p.m. Jan. 7, 2014 - Russ Britt
Gilead, Acura stand out on up day for stocks, Quest tumbles 10:27 a.m. Oct. 10, 2013 - Russ Britt
Health care leads S&P as St. Jude gets some good news from FDA 10:49 a.m. Oct. 4, 2013 - Russ Britt
Rough market day for Nektar, while Pharmacyclics and Regeneron soar 5:21 p.m. Sept. 26, 2013 - Russ Britt
Pharmacyclics shares jump after FDA accepts new cancer drug filing 11:09 a.m. Aug. 29, 2013 - Russ Britt
S&P 500 ventures to uncharted territory 11:21 a.m. July 18, 2013 - Michael Ashbaugh
Pharmacyclics seeks fast-track drug approval, makes double-digit gain 10:09 a.m. July 10, 2013 - Russ Britt
Onyx share surge lifts several boats in biotech harbor, including ETFs 10:33 a.m. July 1, 2013 - Russ Britt
Positives continue to build for the Nasdaq 12:31 p.m. June 4, 2013 - The Trading Deck
For the medium-term trader, setups galore 10:39 a.m. May 14, 2013 - The Trading Deck
After the close: Big gains for Pharmacyclics, Biogen, Warner 4:39 p.m. May 13, 2013 - Russ Britt
FDA gives 'breakthrough' designation to Merck drug 8:10 p.m. April 23, 2013 - MarketWatch.com

Imbruvica performs well in high-risk leukemia patients 12:15 p.m. Jan. 5, 2015 - Seeking Alpha
IMBRUVICA Data Demonstrates Efficacy in Previously Untreated and Relapsed/Refractory High-Risk Chronic Lymphocytic Leukemia Patients 8:02 a.m. Jan. 5, 2015 - benzinga.com
Individual Investor Portfolio: Solid Results, But Energy Sell-Off And Biotechnology Add Volatility 10:45 a.m. Jan. 2, 2015 - Seeking Alpha
Bull of the Day: Incyte (INCY) - Bull of the Day 1:00 a.m. Jan. 2, 2015 - Zacks.com
Idera Gets Orphan Drug Status for its Oncology Candidate - Analyst Blog 4:15 p.m. Dec. 31, 2014 - Zacks.com
DoctoRx Positions For 2015: I Have Cut Back On My Exposure To All Biotech Substantially 7:05 a.m. Dec. 30, 2014 - Seeking Alpha
13 Biotechnology Stocks to Buy Now 3:45 a.m. Dec. 24, 2014 - InvestorPlace.com
Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog 6:05 p.m. Dec. 23, 2014 - Zacks.com
Pharmacyclics (PCYC) Is Water-Logged And Getting Wetter Today 12:10 p.m. Dec. 23, 2014 - TheStreet.com
Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day 1:00 a.m. Dec. 19, 2014 - Zacks.com
11 Biotechnology Stocks to Buy Now 3:15 a.m. Dec. 17, 2014 - InvestorPlace.com
Nasdaq makes annual changes to Biotechnology Index 12:36 p.m. Dec. 15, 2014 - Seeking Alpha
11 Very Popular Stocks Now Valued Over 50 Times Earnings 7:11 a.m. Dec. 10, 2014 - 247WallSt.com
9 Biotechnology Stocks to Buy Now 4:30 a.m. Dec. 10, 2014 - InvestorPlace.com
Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog 5:10 p.m. Dec. 9, 2014 - Zacks.com
Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma 8:02 a.m. Dec. 9, 2014 - benzinga.com
Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog 6:50 p.m. Dec. 8, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? (Revised) - Tale of the Tape 8:35 a.m. Dec. 4, 2014 - Zacks.com
Can Pharmacyclics (PCYC) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape 8:41 a.m. Dec. 3, 2014 - Zacks.com
10 Biotechnology Stocks to Buy Now 4:15 a.m. Dec. 3, 2014 - InvestorPlace.com

Annual Changes to the NASDAQ Biotechnology Index 7:10 a.m. Dec. 15, 2014 - GlobeNewswire
Data From Phase 2 Clinical Trial of TG-1101 (Ublituximab) and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia (CLL) 1:43 p.m. Dec. 8, 2014 - GlobeNewswire
Critical Alerts For Nuverra Environmental Solutions, Marvell Technology, Pharmacyclics, Aeropostale and Rockwell Medical Released By InvestorsObserver 9:31 a.m. Nov. 21, 2014 - PR Newswire - PRF
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA 8:50 a.m. Nov. 7, 2014 - PR Newswire - PRF
Keith Lui Joins Versartis to Lead Global Marketing Efforts 8:32 a.m. Nov. 6, 2014 - GlobeNewswire
Biotech Equities Movers and Shakers - Organovo Holdings, Medivation, Pharmacyclics, Synthetic Biologics, and Ironwood Pharma 7:40 a.m. Oct. 30, 2014 - PR Newswire - PRF
Pharmacyclics Announces Conference Call to Discuss Third Quarter Financial Results 5:11 p.m. Oct. 28, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 8:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Supplemental New Drug Application Submitted to the U.S. FDA for Waldenstrom's macroglobulinemia 7:05 a.m. Oct. 20, 2014 - PR Newswire - PRF
Pharmacyclics Files Supplemental New Drug Application for IMBRUVICA® for Waldenstrom's Macroglobulinemia 7:00 a.m. Oct. 20, 2014 - PR Newswire - PRF
IMBRUVICA® (ibrutinib) Now Approved in Europe for Treatment of Two Blood Cancers 7:49 a.m. Oct. 17, 2014 - PR Newswire - PRF
Biotech Stocks Technical Insight - Incyte, Regado Biosciences, ACADIA Pharma, Pharmacyclics, and Raptor Pharma 7:45 a.m. Sept. 26, 2014 - PR Newswire - PRF
Pharmacyclics and Servier Agree to Conclude Pan-HDAC Inhibitor Collaboration 3:01 p.m. Sept. 25, 2014 - PR Newswire - PRF
New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma 8:15 a.m. Sept. 15, 2014 - PR Newswire - PRF
Financing Strategies, Financing Packages, Recognitions, Technical Updates, and Appointments - Research Reports on Aon, U.S. Bancorp, Ally Financial, Teva and Pharmacyclics 8:10 a.m. Aug. 22, 2014 - PR Newswire - PRF
Pharmacyclics Appoints Chief Commercial Officer 3:05 p.m. Aug. 18, 2014 - PR Newswire - PRF
Technical Summary on Biotech Equities -- Alkermes, Amarin, Array BioPharma, Navidea Biopharma, and Pharmacyclics Inc. 8:00 a.m. Aug. 18, 2014 - PR Newswire - PRF
Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen 7:50 a.m. Aug. 4, 2014 - PR Newswire - PRF
Pharmacyclics Reports Second Quarter 2014 Results 3:04 p.m. July 31, 2014 - PR Newswire - PRF
Critical Alerts For Silicon Motion Technology, Pharmacyclics, 3D Systems, Walgreen, and Neurocrine Biosciences Released By InvestorsObserver 8:31 a.m. July 30, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...